Cargando…
Gabapentin enacarbil extended release for the treatment of postherpetic neuralgia in adults
The development of biomedical technology is allowing refinement of drug therapies in order to improve medication profiles and benefit patients. Gabapentin (Gp) is a medication licensed globally for various indications, including postherpetic neuralgia. It has a pharmacokinetic profile which has been...
Autores principales: | Thomas, Ben M, Farquhar-Smith, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861364/ https://www.ncbi.nlm.nih.gov/pubmed/24353426 http://dx.doi.org/10.2147/TCRM.S50212 |
Ejemplares similares
-
Gabapentin Enacarbil: Pharmacotherapy of Restless Legs Syndrome
por: Jones, Ruth, et al.
Publicado: (2010) -
Review of the Treatment of Restless Legs Syndrome: Focus on Gabapentin Enacarbil
por: Burke, Rachel A., et al.
Publicado: (2012) -
Role of gabapentin enacarbil XR in restless legs syndrome
por: Sivam, Sheila, et al.
Publicado: (2012) -
Gabapentin Enacarbil Extended‐Release Versus Placebo: A Likely Responder Reanalysis of a Randomized Clinical Trial
por: Laska, Eugene M., et al.
Publicado: (2020) -
Gabapentin enacarbil – clinical efficacy in restless legs syndrome
por: Agarwal, Pinky, et al.
Publicado: (2010)